Jin-Wei Miao1, Xiao-Hong Deng. 1. Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100006, China.
Abstract
OBJECTIVE: To present patterns of practice and outcomes in the adjuvant treatment of intermediate- and high-risk endometrial cancer. METHODS: Retrospective data on 224 women with intermediate-risk and high-risk endometrial cancer from 1999 to 2006 were reviewed. All patients underwent surgical staging. Patterns of adjuvant treatment, consisting of pelvic radiotherapy, chemotherapy, and radiotherapy plus chemotherapy, were assessed. The 3- and 5-year disease-specific survival (DSS) rates were calculated using the Kaplan-Meier method. RESULTS: The difference in 5-year DSS rate was statistically significant between adjuvant group and non-adjuvant group (80.65% vs. 63.80%, P=0.040). In 110 high-risk patients who underwent adjuvant treatment, both 5-year DSS rate and recurrent rate were significantly different in combined radiotherapy and chemotherapy group compared with radiotherapy alone and chemotherapy alone groups (DSS rate, P=0.049; recurrent rate, P=0.047). In 83 intermediate-risk women who underwent adjuvant treatment, there was no significant difference in 5-year DSS rate and recurrence rate among the combined radiotherapy and chemotherapy, radiotherapy alone and chemotherapy alone groups (DSS rate, P=0.776; recurrent rate, P=0.937). CONCLUSIONS: Adjuvant radiotherapy plus chemotherapy is associated with a higher 5-year DSS rate and lower recurrence rate compared with radiotherapy alone and chemotherapy alone in high-risk endometrial cancer patients. Patients with intermediate-risk endometrial cancer may be not likely to benefit from adjuvant combined radiotherapy and chemotherapy.
OBJECTIVE: To present patterns of practice and outcomes in the adjuvant treatment of intermediate- and high-risk endometrial cancer. METHODS: Retrospective data on 224 women with intermediate-risk and high-risk endometrial cancer from 1999 to 2006 were reviewed. All patients underwent surgical staging. Patterns of adjuvant treatment, consisting of pelvic radiotherapy, chemotherapy, and radiotherapy plus chemotherapy, were assessed. The 3- and 5-year disease-specific survival (DSS) rates were calculated using the Kaplan-Meier method. RESULTS: The difference in 5-year DSS rate was statistically significant between adjuvant group and non-adjuvant group (80.65% vs. 63.80%, P=0.040). In 110 high-risk patients who underwent adjuvant treatment, both 5-year DSS rate and recurrent rate were significantly different in combined radiotherapy and chemotherapy group compared with radiotherapy alone and chemotherapy alone groups (DSS rate, P=0.049; recurrent rate, P=0.047). In 83 intermediate-risk women who underwent adjuvant treatment, there was no significant difference in 5-year DSS rate and recurrence rate among the combined radiotherapy and chemotherapy, radiotherapy alone and chemotherapy alone groups (DSS rate, P=0.776; recurrent rate, P=0.937). CONCLUSIONS: Adjuvant radiotherapy plus chemotherapy is associated with a higher 5-year DSS rate and lower recurrence rate compared with radiotherapy alone and chemotherapy alone in high-risk endometrial cancerpatients. Patients with intermediate-risk endometrial cancer may be not likely to benefit from adjuvant combined radiotherapy and chemotherapy.
Authors: Marcus E Randall; Virginia L Filiaci; Hyman Muss; Nick M Spirtos; Robert S Mannel; Jeffrey Fowler; J Tate Thigpen; Jo Ann Benda Journal: J Clin Oncol Date: 2005-12-05 Impact factor: 44.544
Authors: Nita Karnik Lee; Michael K Cheung; Jacob Y Shin; Amreen Husain; Nelson N Teng; Jonathan S Berek; Daniel S Kapp; Kathryn Osann; John K Chan Journal: Obstet Gynecol Date: 2007-03 Impact factor: 7.661
Authors: B Röper; S T Astner; A Heydemann-Obradovic; R Thamm; V Jacob; D Hölzel; B Schmalfeldt; M Kiechle-Bahat; C Höss; M Molls Journal: Gynecol Oncol Date: 2007-09-20 Impact factor: 5.482
Authors: Nadeem R Abu-Rustum; Dennis S Chi; Mario Leitao; Eniola A Oke; Martee L Hensley; Kaled M Alektiar; Richard R Barakat Journal: Gynecol Oncol Date: 2008-07-26 Impact factor: 5.482
Authors: Henry M Keys; James A Roberts; Virginia L Brunetto; Richard J Zaino; Nick M Spirtos; Jeffrey D Bloss; Andrew Pearlman; Mitchell A Maiman; Jeffrey G Bell Journal: Gynecol Oncol Date: 2004-03 Impact factor: 5.482
Authors: Lisa N Abaid; Mark A Rettenmaier; John V Brown; John P Micha; Alberto A Mendivil; Marie A Wabe; Bram H Goldstein Journal: J Gynecol Oncol Date: 2012-01-09 Impact factor: 4.401